Cargando…

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics

BACKGROUND: Oral drug formulations have several advantages compared to intravenous formulation. Apart from patient convenience and favorable pharmacoeconomics, they offer the possibility of frequent drug administration at home. In this study, we present a new oral irinotecan formulation designed as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kümler, I., Sørensen, P. Grundtvig, Palshof, J., Høgdall, E., Skovrider-Ruminski, W., Theile, S., Fullerton, A., Nielsen, P. G., Jensen, B. Vittrup, Nielsen, D. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373187/ https://www.ncbi.nlm.nih.gov/pubmed/30406838 http://dx.doi.org/10.1007/s00280-018-3720-7

Ejemplares similares

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2017)

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2020)

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
por: Skougaard, Kristin, et al.
Publicado: (2014)

The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis
por: Ingerslev, Kasper, et al.
Publicado: (2017)

The prevalence of EBV and CMV DNA in epithelial ovarian cancer
por: Ingerslev, Kasper, et al.
Publicado: (2019)

High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population
por: Ingerslev, Kasper, et al.
Publicado: (2016)

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2017)

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
por: Kümler, Iben, et al.
Publicado: (2019)

Pharmacokinetics of escalating single‐dose administration of cannabidiol to cats
por: Rozental, Aaron J., et al.
Publicado: (2022)

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol
por: Kümler, Iben, et al.
Publicado: (2015)

Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model
por: Lewis, Andrew L., et al.
Publicado: (2012)

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
por: Demuth, Christina, et al.
Publicado: (2018)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
por: Wu, Huali, et al.
Publicado: (2015)

Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study
por: Tanaka, Toshihiro, et al.
Publicado: (2019)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver
por: Melancon, Marites P., et al.
Publicado: (2021)

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
por: Bendell, Johanna C, et al.
Publicado: (2015)

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
por: Chiang, Nai-Jung, et al.
Publicado: (2016)

An Open‐label Phase 1 Dose‐escalation Clinical Trial of a Single Intravenous Administration of Gemcitabine in Dogs with Advanced Solid Tumors
por: Marconato, L., et al.
Publicado: (2015)

A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
por: Theile, Susann, et al.
Publicado: (2022)

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
por: Cecchini, Michael, et al.
Publicado: (2023)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Publicado: (2019)

A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors
por: Gbolahan, Olumide B., et al.
Publicado: (2022)

Influenza and cardiovascular disease pathophysiology: strings attached
por: Skaarup, Kristoffer Grundtvig, et al.
Publicado: (2023)

Phase 1 dose-escalation study of apatinib and irinotecan in esophageal squamous cell carcinoma patients
por: Jia, Jun, et al.
Publicado: (2021)

Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation
por: Yang, Wenqian, et al.
Publicado: (2019)

Formulation and Evaluation of Irinotecan Suppository for Rectal Administration
por: Feng, Haiyang, et al.
Publicado: (2014)

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
por: Mathijssen, R H J, et al.
Publicado: (2002)

Pharmacokinetics of zonisamide after oral single dosing and multiple‐dose escalation administration in domestic chickens (Gallus gallus)
por: de Matos, Ricardo, et al.
Publicado: (2021)

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3(rd) Line Cetuximab and Irinotecan
por: Schou, Jakob V., et al.
Publicado: (2014)

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
por: Padda, Sukhmani K., et al.
Publicado: (2011)

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
por: de Man, Femke M., et al.
Publicado: (2018)

A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours
por: Lassen, U, et al.
Publicado: (2012)

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
por: Bozionelou, V, et al.
Publicado: (2007)

Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
por: Saunders, M P, et al.
Publicado: (2004)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
por: Allegrini, G, et al.
Publicado: (2008)

Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
por: Sy, S. Kenneth, et al.
Publicado: (2016)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995)

Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body
por: Fan, Yingfang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n635c7sulq0v25c1tjbnlv2uoh